COMPASS Pathways plc CMPS

CMPS Company Overview

COMPASS Pathways plc is a biotechnology and mental health care company focused on developing evidence-based psychedelic therapies for treatment-resistant mental health conditions. The company primarily operates within the biopharmaceutical and neuropsychiatric treatment industries, with a strategic emphasis on psilocybin-assisted therapy for patients with treatment-resistant depression (TRD) and related psychiatric disorders. Its core asset is COMP360, a proprietary synthetic psilocybin formulation administered in conjunction with psychological support protocols designed for clinical settings.

The company’s primary revenue and enterprise value drivers are tied to the advancement, regulatory approval, and commercialization potential of its investigational therapies, particularly COMP360. COMPASS Pathways serves healthcare systems, psychiatric providers, research institutions, and patients with severe mental health disorders who have not responded adequately to conventional treatments. The company was founded in 2016 by George Goldsmith and Ekaterina Malievskaia following personal experiences related to mental health treatment gaps. Since inception, it has evolved from an early-stage psychedelic research company into a publicly traded clinical-stage biotechnology company listed on Nasdaq under the ticker CMPS.